Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Satsuma Pharmaceuticals Inc (STSA)

Satsuma Pharmaceuticals Inc (STSA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 36,467
  • Shares Outstanding, K 33,152
  • Annual Sales, $ 0 K
  • Annual Income, $ -70,060 K
  • 60-Month Beta 0.10
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.97
Trade STSA with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -2.01
  • Most Recent Earnings $-0.31 on 05/11/23
  • Next Earnings Date 05/16/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate -0.25
  • Number of Estimates 1
  • High Estimate -0.25
  • Low Estimate -0.25
  • Prior Year -0.52
  • Growth Rate Est. (year over year) +51.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0100 +8.91%
on 06/07/23
1.1400 -3.51%
on 06/07/23
+0.0300 (+2.80%)
since 05/05/23
3-Month
0.6550 +67.94%
on 04/14/23
1.4700 -25.17%
on 04/17/23
+0.1531 (+16.17%)
since 03/07/23
52-Week
0.5900 +86.44%
on 11/14/22
8.0800 -86.39%
on 09/22/22
-2.0700 (-65.30%)
since 06/07/22

Most Recent Stories

More News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HSKA, TESS, NATI, STSA

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

HSKA : 119.99 (+0.04%)
TESS : 8.99 (+0.11%)
NATI : 59.98 (unch)
STSA : 1.1000 (-0.90%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MGTA, CHRA, STSA

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

MGTA : 11.1936 (-7.74%)
STSA : 1.1000 (-0.90%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HSKA, TESS, NATI, STSA

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

HSKA : 119.99 (+0.04%)
TESS : 8.99 (+0.11%)
NATI : 59.98 (unch)
STSA : 1.1000 (-0.90%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TESS, STSA, CHRA

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

TESS : 8.99 (+0.11%)
STSA : 1.1000 (-0.90%)
Shareholder Alert: Ademi LLP investigates whether Satsuma Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Shin Nippon

/PRNewswire/ -- Ademi LLP is investigating Satsuma (NASDAQ: STSA) for possible breaches of fiduciary duty and other violations of law in its transaction with...

STSA : 1.1000 (-0.90%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NATI, RXDX, STSA, CHRA

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

NATI : 59.98 (unch)
RXDX : 199.92 (+0.09%)
STSA : 1.1000 (-0.90%)
SATSUMA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Satsuma Pharmaceuticals, Inc. - STSA

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Satsuma Pharmaceuticals, Inc. (“Satsuma”)...

STSA : 1.1000 (-0.90%)
Moore Kuehn Encourages BLU, STSA, RXDX, STSA, and CHRA Investors to Contact Law Firm

/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...

BLU : 14.74 (unch)
STSA : 1.1000 (-0.90%)
RXDX : 199.92 (+0.09%)
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates RXDX, STSA, CHRA

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

RXDX : 199.92 (+0.09%)
STSA : 1.1000 (-0.90%)
STSA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Satsuma Pharmaceuticals, Inc. Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Satsuma Pharmaceuticals, Inc. (NASDAQ: STSA) to Shin Nippon Biomedical Laboratories, Ltd. for $0.91 in cash per share...

STSA : 1.1000 (-0.90%)

Business Summary

Satsuma Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It develops novel therapeutic products for the acute treatment of migraine. The company's product consists of STS101, which are in clinical stage. Satsuma Pharmaceuticals Inc. is based in San Francisco, United States.

See More

Key Turning Points

3rd Resistance Point 1.2867
2nd Resistance Point 1.2133
1st Resistance Point 1.1567
Last Price 1.1000
1st Support Level 1.0267
2nd Support Level 0.9533
3rd Support Level 0.8967

See More

52-Week High 8.0800
Fibonacci 61.8% 5.2188
Fibonacci 50% 4.3350
Fibonacci 38.2% 3.4512
Last Price 1.1000
52-Week Low 0.5900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar